Bone Biologics (OTC:BBLG – Get Rating) and Sientra (NASDAQ:SIEN – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bone Biologics and Sientra, as reported by MarketBeat.

Bone Biologics presently has a consensus target price of $2.25, indicating a potential upside of 892.94%. Sientra has a consensus target price of $5.19, indicating a potential upside of 2,098.27%. Given Sientra's higher possible upside, analysts plainly believe Sientra is more favorable than Bone Biologics.

Profitability

Insider & Institutional Ownership

0.5% of Bone Biologics shares are held by institutional investors. Comparatively, 68.4% of Sientra shares are held by institutional investors. 1.3% of Sientra shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Bone Biologics and Sientra's revenue, earnings per share (EPS) and valuation.

Bone Biologics has higher earnings, but lower revenue than Sientra.

Risk and Volatility

Bone Biologics has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Sientra has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.

Summary

Sientra beats Bone Biologics on 6 of the 11 factors compared between the two stocks.

About Bone Biologics

(Get Rating)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

About Sientra

(Get Rating)

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.